Prostate Cancer Topics

The On-Topic Netowork

Prostate Cancer > Angiogenesis

The following information is about Angiogenesis.

Angiogenesis Defined

The growth of new blood vessels; a characteristic of tumors; angiogenesis is normal biologic process that occurs in both healthy and disease states; “angiogenesis factor” or “tumor angiogenesis factor” refers to a substance that tumors produce in order to grow new blood vessels

This definition is in context to Prostate Cancer. See more contextual defintions for Angiogenesis.


2009 Dr. Paul Janssen Award For Biomedical Research Won By Axel Ullrich

Published July 2, 2009, 8:09 am, Medical News Today

Johnson & Johnson has announced that Axel Ullrich, Ph.D., director of the Department of Molecular Biology at the Max Planck Institute of Biochemistry in Germany, whose discoveries have led to novel cancer therapies including Herceptin® (trastuzumab) , is the winner of the 2009 Dr. Paul Janssen Award for Biomedical Research. An independent committee of world-renowned scientists selected Dr.

Full Story


Pfizer Discontinues Phase 3 Trial Of Sutent(R) In Metastatic Colorectal Cancer

Published July 2, 2009, 4:09 am, Medical News Today

Pfizer Inc announced the discontinuation of the SUN 1122 Phase 3 trial that evaluated Sutent® (sunitinib malate) plus FOLFIRI (irinotecan plus infusional 5-fluorouracil and leucovorin) versus FOLFIRI alone for the first-line treatment of metastatic colorectal cancer (CRC).

Full Story


02.07.2009 - DJ DGAP-Adhoc: TopoTarget completes fully subscribed rights issue

Published July 2, 2009, 12:44 am, 4investors

Release of a Adhoc News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. =--------------------------------------------------------------------------

Full Story


Video: Axel Ullrich Named Winner of 2009 Dr. Paul Janssen Award for Biomedical Research

Published July 1, 2009, 11:30 am, redOrbit

LONDON, July 1 /PRNewswire/ -- Johnson & Johnson today announced that Axel Ullrich, Ph.D., director of the Department of Molecular Biology at the Max Planck Institute of Biochemistry in Germany, whose discoveries have led to novel cancer therapies including Herceptin(R) (trastuzumab)*, is the winner of the 2009 Dr.

Full Story


Axel Ullrich named winner of 2009 Dr. Paul Janssen Award for Biomedical Research

Published July 1, 2009, 10:14 am, EurekAlert!

( Porter Novelli ) Johnson & Johnson announced that Axel Ullrich, Ph.D., director of the Department of Molecular Biology at the Max Planck Institute of Biochemistry in Germany, whose discoveries have led to novel cancer therapies including Herceptin (trastuzumab), is the winner of the 2009 Dr. Paul Janssen Award for Biomedical Research. An independent committee of world-renowned scientists ...

Full Story


Sutent Significantly Improved Progression-Free Survival For Patients With Advanced Pancreatic Islet Cell Tumours

Published July 1, 2009, 4:08 am, Medical News Today

Pfizer announced preliminary results from a randomized Phase 3 trial of Sutent (sunitinib malate) in patients with advanced pancreatic islet cell tumours, also known as pancreatic neuroendocrine tumours, which is a different type of cancer than the more common pancreatic adenocarcinoma. Study findings demonstrated that median progression-free survival (PFS) was 11.

Full Story


European Regulator Gives Positive Opinion for the use of Avastin in Combination With docetaxel for the First-Line ...

Published June 28, 2009, 7:39 pm, Thaipr.net

Patients with advanced (metastatic) breast cancer will be able to benefit from treatment with Avastin (bevacizumab) as a result of a new broader label recommendation in Europe, Roche announced today.

Full Story


Are you looking for additional Prostate Cancer > Angiogenesis news? Try our new "Angiogenesis News Focus" area.

Off-site Angiogenesis Links, User Submitted

The following links have been collected through user bookmark submission in the Angiogenesis category. Please note, because these resources are off-site we cannot guarantee the accuracy or quality of any information.

Sun Jun 28

Wed Jun 24

Mon Jun 22

Sat Jun 13

Thu Jun 11

  • Gene Therapy Technique Thwarts Cancer By Cutting Off Tumor Blood Supply: ScienceDaily (June 11, 2009) ? University of Florida researchers have come up with a new gene therapy method to disrupt cancer growth by using a synthetic protein to induce blood clotting that cuts off a tumor's blood and nutrient supply. In mice implanted with human colorectal cancer cells, tumor volume decreased 53 percent and cancer cell growth slowed by 49 percent in those treated with a gene that encodes for the artificial protein, compared with those that were untreated.

Wed Jun 10

  • UNC scientists identify growth factor as possible cancer drug target: Scientists at the UNC Lineberger Comprehensive Cancer Center report finding a new angiogenesis protein, SFRP2, found in the blood vessels of numerous tumor sites, including breast prostate, lung, pancreas, ovarian, colon, kidney tumors, and angiosarcomas. The scientists found that SFRP2 is a potent stimulator of angiogenesis. This protein may be a favorable target for inhibiting angiogenesis which would then "starve&q uot; the tumor of its blood supply, thus destroying the cancer.

Mon Jun 8

Thu May 28

If you would like to find additional social bookmark based links on the topic of we recommend the Open Tag Directory > Angiogenesis. If you would like to find related tags we recommend Tag Patterns > Angiogenesis

Off-site Angiogenesis Research Links

If you still need additional information on Angiogenesis then we suggest the following off-site resources. Please note, because these resources are off-site we cannot guarantee the accuracy or quality of any information.

Prostate Cancer

If you know the Prostate Cancer Term Name use the links below to quickly jump to your desired focus.



Bookmark Us

The On Topic Network

This website is part of The On Topic Network.

Thank You

Prostate-Cancer.On-Topic.net was developed by Odin Metatech, Inc and runs on the Odin Assemble platform.

License

Creative Commons License This work is licensed under Creative Commons.


Your Ad Here
Your Ad Here

Powered by Odin Assemble 2.5a